Key references: Assessing suitability of intrauterine contraceptive devices

Family Planning Alliance Australia (FPAA). How effective is my contraceptive method? Brisbane, Queensland: FPAA; 2019. https://www.familyplanningallianceaustralia.org.au/larc/
Goldthwaite LM, Creinin MD. Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems. Contraception 2019;100(2):128–31. https://www.ncbi.nlm.nih.gov/pubmed/31051118
Nelson A, Apter D, Hauck B, Schmelter T, Rybowski S, Rosen K, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol 2013;122(6):1205–13. https://www.ncbi.nlm.nih.gov/pubmed/24240244
Schaffir J, Worly BL, Gur TL. Combined hormonal contraception and its effects on mood: a critical review. Eur J Contracept Reprod Health Care 2016;21(5):347–55. https://www.ncbi.nlm.nih.gov/pubmed/27636867
Skovlund CW, Morch LS, Kessing LV, Lidegaard O. Association of hormonal contraception with depression. JAMA Psychiatry 2016;73(11):1154–62. https://www.ncbi.nlm.nih.gov/pubmed/27680324
The Faculty of Sexual & Reproductive Healthcare (FSRH). UK medical eligibility criteria (UKMEC) for contraceptive use. London: FSRH; 2016 (Amended 2019). https://www.fsrh.org/standards-and-guidance/uk-medical-eligibility-criteria-for-contraceptive-use-ukmec/
The Faculty of Sexual & Reproductive Healthcare (FSRH) Clinical Effectiveness Unit. Clinical guidance: Intrauterine contraception. London: FSRH; 2015 (Amended 2019). https://www.fsrh.org/standards-and-guidance/documents/ceuguidanceintrauterinecontraception/
The Faculty of Sexual & Reproductive Healthcare (FSRH) Clinical Effectiveness Unit. New product review: Kyleena 19.5 mg intrauterine delivery system. Edinburgh: FSRH; 2018 (Amended 2019). https://www.fsrh.org/documents/fsrh-ceu-new-product-review-kyleena-january-2018/